Synapse - Mark Kris

Results (869)

Characteristics of NSCLCs harboring NRAS mutations

Meeting Abstract

Ohashi, K.; Sequist, L. V.; Sos, M.; Chen, X.; Rudin, C. M.; Moran, T.; Arcila, M. E.; Lovly, C. M.; Vnencak-Jones, C. L.; Sasaki, H.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers

Meeting Abstract

Kris, M. G.; Mok, T.; Ou, S. H. I.; Martins, R.; Kim, D. W.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, S. P.; Janne, P. A.
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)

Meeting Abstract

Johnson, M. L.; Yu, H. A.; Hart, E. M.; Worden, R.; Rademaker, A.; Gupta, R.; Miller, C.; Patel, J. D.; Kris, M. G.; Miller, V. A.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial

Meeting Abstract

Drilon, A. E. D. C.; Kyuichi, K.; Huberman, K. H.; Sima, C. S.; Fiore, J. J.; Yu, H. A.; Varghese, A. M.; Sumner, D. K.; Travis, W. D.; Heguy, A.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Quantitating pathologic response to neoadjuvant chemotherapy in KRAS-mutated versus nonmutated lung cancers

Meeting Abstract

Chaft, J. E.; Paik, P. K.; Sima, C. S.; Kris, M. G.; Krug, L. M.; Azzoli, C. G.; Riely, G. J.; Pietanza, M. C.; Rusch, V. W.; Travis, W. D.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

EGFR exon 20 insertion mutations: Incidence and clinicopathologic characteristics in US patients with lung adenocarcinoma

Meeting Abstract

Arcila, M. E.; Nafa, K.; Chaft, J. E.; Rekhtman, N.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Prospective study of tumor suppressor gene (TSG) methylation as a prognostic biomarker in surgically resected non-small cell lung cancer (NSCLC)

Meeting Abstract

Azzoli, C. G.; Drilon, A. E. D.; Sugita, H.; Sima, C. S.; Huang, E.; Danenberg, P. V.; Kris, M. G.; Rusch, V. W.
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Antiemetic use in oncology: Updated guideline recommendations from ASCO

Journal Article

Basch, E.; Prestrud, A. A.; Hesketh, P. J.; Kris, M. G.; Somerfield, M. R.; Lyman, G. H.
American Society of Clinical Oncology Educational Book (2012)

Fulltext@MSK | Save

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers

Meeting Abstract

Kris, M. G.; Mok, T.; Ou, S. H. I.; Martins, R. G.; Kim, D. W.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, S. P.; Jänne, P. A.
Annals of Oncology (2012)

Fulltext@MSK | Save

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions

Journal Article

Suehara, Y.; Arcila, M.; Wang, L.; Hasanovic, A.; Ang, D.; Ito, T.; Kimura, Y.; Drilon, A.; Guha, U.; Rusch, V.; more...
Clinical Cancer Research (2012)

Fulltext@MSK | Save